How to compete and win in a world of biosimilars

How to compete and win in a world of biosimilars

A relatively new part of the pharma industry, biosimilars are coming to the U.S.


Related content

Molecular view

By Mark Ginestro, Principal, KPMG Strategy and Jason Moore, Manager, KPMG Strategy

This nascent market is poised for huge growth, and no doubt, biosimilars will be a disrupter. The challenge companies need to face now is how they will adapt their commercial strategies to be successful. In this paper, we detail a range of possible commercial approaches, while also addressing the issues of partnering, regulatory developments and go-to-market considerations. 

Want to know more?

Download the report (PDF 1.8 MB). And if you want to talk, we’d be happy to hear from you.

Connect with us


Request for proposal



KPMG's new digital platform

KPMG International has created a state of the art digital platform that enhances your experience, optimized to discover new and related content.